Work

Association of estimated glucose disposal rate with atrial fibrillation, heart failure and cardiovascular mortality in patients with diabetes: a prospective cohort study from the UK Biobank

Year: 2025

Type: article

Abstract: Background: Estimated glucose disposal rate (eGDR) was a novel non-insulin-based marker of insulin resistance (IR), which had been used in many studies to evaluate the clinical prognosis of diabetes. However, the association of eGDR with atrial fibrillation (AF), heart failure (HF) and cardiovascular mortality in patients with diabetes remains unclear. Methods: The study utilized UK Biobank data from 31,733 participants. Kaplan-Meier curves and Log-rank tests assessed AF, HF, and cardiovascular mortality incidence. Multivariate Cox models and restricted cubic splines analyzed the associations of eGDR with these outcomes. Polygenic Risk Score (PRS) analysis evaluated the joint effects of eGDR and PRS. Boruta algorithm filtered key predictive variables. Subgroup analysis was performed using cardiovascular high-risk factors, and mediation analysis explored the relationships of eGDR with the outcomes. Results: < 0.001 for all). eGDR exhibited an independent negative linear correlation with the risk of AF (HR = 0.94, 95% CI: 0.91-0.96), HF (HR = 0.78, 95% CI: 0.74-0.82), and cardiovascular mortality (HR = 0.86, 95% CI: 0.83-0.88) risk. eGDR made the most significant contribution to the predicted outcomes. In diabetic patients with high genetic susceptibility, high eGDR could reduce the risk of AF (HR = 0.68, 95% CI: 0.51-0.90), HF (HR = 0.43, 95% CI: 0.29-0.62), and cardiovascular mortality (HR = 0.30, 95% CI: 0.22-0.42). Mediation analysis demonstrated that 10.7%, 7.9%, and 10.3% of the relationship between eGDR and AF, HF, and cardiovascular mortality among individuals with diabetes were mediated by eGFR, respectively. Conclusions: This study demonstrated that higher eGDR levels were associated with a decreased risk of AF, HF, and cardiovascular mortality. Therefore, eGDR may serve as a valuable tool for predicting the risk of AF, HF, and cardiovascular mortality in patients with diabetes.

Source: Frontiers in Endocrinology

DOI: 10.3389/fendo.2025.1579836